SERENITY III will evaluate the efficacy and safety of BXCL501 for at-home use
Top-line pivotal data expected in 1H 2023
Estimated 23 million annual agitation episodes in the home-setting would more than double current market opportunity for BXCL501 in the U.S. 1-4
https://finance.yahoo.com/news/bioxcel-therapeutics-announces-first-patients-120000182.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.